BridgeBio Pharma BBIO
Kumar Haldea Revocabletrust U/A DTD 12/19/2018 (Director) plans to sell 120,000 BBIO shares, about $5.2M
- Form
- 144
- Filed
- Importance
- Routine
- Accession
- 0001950047-25-004775
- Document
- Form 144
- Approximate sale date: Jul 1, 2025
- Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
- Shares acquired by: Conversion Management Incentive Units
- 10b5-1 plan adopted: Mar 31, 2025
All of Kumar Haldea Revocabletrust U/A DTD 12/19/2018's insider filings, holdings and planned sales
Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):
- Sold 11,795 shares at $45.88 on Aug 8, 2025 · Form 4
- Sold 8,205 shares at $46.71 on Aug 8, 2025 · Form 4
- Sold 25,728 shares at $48.81 on Aug 20, 2025 · Form 4
- Sold 14,525 shares at $51.15 on Sep 4, 2025 · Form 4
- Sold 5,475 shares at $51.85 on Sep 4, 2025 · Form 4
- Sold 14,558 shares at $51.16 on Sep 4, 2025 · Form 4
- Sold 5,442 shares at $51.85 on Sep 4, 2025 · Form 4
- Sold 16,800 shares at $53.16 on Sep 5, 2025 · Form 4
- Sold 900 shares at $53.8 on Sep 5, 2025 · Form 4
- Sold 2,300 shares at $51.96 on Sep 5, 2025 · Form 4
- Sold 800 shares at $53.8 on Sep 5, 2025 · Form 4
Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025
- Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
- Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
- Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
- Repligen RGEN public float $6.0B, Jun 30, 2025
